CCND2 rearrangements are the most frequent genetic events in cyclin D1(-) mantle cell lymphoma.
暂无分享,去创建一个
A. Rosenwald | W. Klapper | R. Siebert | P. Gaulard | A. López-Guillermo | E. Campo | N. Harris | G. Ott | E. Jaffe | S. Beà | G. Clot | A. Navarro | C. Royo | I. Salaverria | L. Quintanilla‐Martinez | E. Hartmann | P. Sujobert | J. Song | J. Ferry | G. Rymkiewicz | R. Woroniecka | I. Wlodarska | A. Valera | Alejandra Carvajal-Cuenca
[1] L. Colomo,et al. SOX11 is useful in differentiating cyclin D1‐positive diffuse large B‐cell lymphoma from mantle cell lymphoma , 2012, Histopathology.
[2] L. Staudt,et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics , 2012, Nature.
[3] E. Giné,et al. Non-nodal type of mantle cell lymphoma is a specific biological and clinical subgroup of the disease , 2012, Leukemia.
[4] K. Fu,et al. Cyclin D1-negative Blastoid Mantle Cell Lymphoma Identified by SOX11 Expression , 2012, The American journal of surgical pathology.
[5] R. Warnke,et al. In situ mantle cell lymphoma: clinical implications of an incidental finding with indolent clinical behavior , 2012, Haematologica.
[6] M. Dreyling,et al. Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma. , 2011, Blood.
[7] A. Rosenwald,et al. The complex landscape of genetic alterations in mantle cell lymphoma. , 2011, Seminars in cancer biology.
[8] Raul Rabadan,et al. Analysis of the Coding Genome of Diffuse Large B-Cell Lymphoma , 2011, Nature Genetics.
[9] Juliane C. Dohm,et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia , 2011, Nature.
[10] A. Feldman,et al. CD5-positive, cyclinD1-negative mantle cell lymphoma with a translocation involving the CCND2 gene and the IGL locus. , 2011, Cancer genetics.
[11] L. Staudt,et al. Pathway discovery in mantle cell lymphoma by integrated analysis of high-resolution gene expression and copy number profiling. , 2010, Blood.
[12] Lin He,et al. mir-17-92, a cluster of miRNAs in the midst of the cancer network. , 2010, The international journal of biochemistry & cell biology.
[13] A. Rosenwald,et al. Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. , 2010, Cancer research.
[14] X. Troussard,et al. Waved aCGH: to smooth or not to smooth , 2010, Nucleic acids research.
[15] Yasodha Natkunam,et al. Characterization of D-Cyclin Proteins in Hematolymphoid Neoplasms: Lack of Specificity of Cyclins D2 and D3 Expression in Lymphoma Subtypes , 2009, Modern Pathology.
[16] W. Klapper,et al. Differential diagnosis of cyclin D2+ mantle cell lymphoma based on fluorescence in situ hybridization and quantitative real-time-PCR , 2009, Haematologica.
[17] Elin Gustavsson,et al. Strong lymphoid nuclear expression of SOX11 transcription factor defines lymphoblastic neoplasms, mantle cell lymphoma and Burkitt’s lymphoma , 2009, Haematologica.
[18] L. Staudt,et al. SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype , 2009, Haematologica.
[19] A. Rosenwald,et al. MicroRNA expression, chromosomal alterations, and immunoglobulin variable heavy chain hypermutations in Mantle cell lymphomas. , 2009, Cancer research.
[20] R. Bellazzi,et al. Different molecular mechanisms causing 9p21 deletions in acute lymphoblastic leukemia of childhood , 2009, Human Genetics.
[21] Xavier Estivill,et al. Uniparental disomies, homozygous deletions, amplifications, and target genes in mantle cell lymphoma revealed by integrative high-resolution whole-genome profiling. , 2009, Blood.
[22] H. Pospíšilová,et al. Translocations targeting CCND2, CCND3, and MYCN do occur in t(11;14)-negative mantle cell lymphomas. , 2008, Blood.
[23] L. de Leval,et al. Cyclin D1-negative mantle cell lymphoma with cryptic t(12;14)(p13;q32) and cyclin D2 overexpression. , 2008, Blood.
[24] Karin Jirström,et al. From bloodjournal.hematologylibrary.org at PENN STATE UNIVERSITY on February 28, 2013. For personal use only. , 2006 .
[25] E. Campo,et al. Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics , 2007, Nature Reviews Cancer.
[26] L. Staudt,et al. Specific secondary genetic alterations in mantle cell lymphoma provide prognostic information independent of the gene expression-based proliferation signature. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] D. Weisenburger,et al. A chromosomal translocation in cyclin D1-negative/cyclin D2-positive mantle cell lymphoma fuses the CCND2 gene to the IGK locus. , 2006, Blood.
[28] L. Staudt,et al. Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. , 2005, Blood.
[29] H. Tagawa,et al. A microRNA cluster as a target of genomic amplification in malignant lymphoma , 2005, Leukemia.
[30] L. Staudt,et al. Cyclin D 1 – negative mantle cell lymphoma : a clinicopathologic study based on gene expression profiling , 2005 .
[31] F Solé,et al. Cyclin D3 is a target gene of t(6;14)(p21.1;q32.3) of mature B-cell malignancies. , 2001, Blood.
[32] A. Rosenwald,et al. Recurrent genetic aberrations in thymoma and thymic carcinoma. , 2000, The American journal of pathology.
[33] Shigeo Nakamura,et al. Significance of cyclin D1 overexpression for the diagnosis of mantle cell lymphoma: a clinicopathologic comparison of cyclin D1-positive MCL and cyclin D1-negative MCL-like B-cell lymphoma , 2000 .
[34] A. López-Guillermo,et al. Increased number of chromosomal imbalances and high-level DNA amplifications in mantle cell lymphoma are associated with blastoid variants. , 1999, Blood.